Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a research note released on Wednesday. The brokerage issued a sell rating on the stock.

Oragenics Price Performance

Shares of Oragenics stock opened at $0.30 on Wednesday. The business has a 50-day simple moving average of $0.34 and a 200-day simple moving average of $0.62. Oragenics has a one year low of $0.25 and a one year high of $6.22.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.